Beam Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
238 Main St, Cambridge, Massachusetts, 0...Phone Number
(857) 327-8775Website
www.beamtx.comRevenue
$156 MillionStock Symbol
BEAMIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
5
2
2
3
3
2
About Beam Therapeutics
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing. The company advances research and clinical programs aimed at providing durable treatments for serious diseases, supported by scientific leadership and drug development capabilities. Beam focuses on translating genome editing science into potential lifelong therapies for patients.Explore more
Beam Therapeutics Org Chart
JM
Senior VP, Legal Affairs
LJ
Vice President, Corporate Counsel
EC
Vice President & Head of Intellectual Propert...
SR
Vice President, Legal
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Beam Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Beam Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Beam Therapeutics has new funding data
Product Launch: Get notified when Beam Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Beam Therapeutics recently announced quarterly report
Check if Beam Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Beam Therapeutics
Website visits: Recent activity has been detected on your website
Beam Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Beam Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Beam Therapeutics
Find 3 more new buyers
Compare Similar Companies to Beam Therapeutics
Compare insights from companies similar to Beam Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Beam Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Beam Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Beam Therapeutics.
Beam Therapeutics financials insights
Gather financial insights about Beam Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$87M
2019
Series B
$135M
2020
Stock Offering
$207M
Stock Offering
$117.5M
2021
Share Placement
$260M
2026
Debt
$500M
Beam Therapeutics Tech Stack
A closer look at the technologies used by Beam Therapeutics
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Person-Based
Events
Open Position
Beam Therapeutics News & Media
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Beam Therapeutics Inc. (BEAM) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 1:00 PM EDTCompany ParticipantsSravan Emany - Chief...Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency September 8, 2026 7:00 AM EDTCompany...Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Beam Therapeutics
Sign Up For FreeTo access detailed company insights
Beam Therapeutics is a biotechnology company developing precision genetic medicines using base editing. The company advances research and clinical programs aimed at providing durable treatments for serious diseases, supported by scientific leadership and drug development capabilities. Beam focuses on translating genome editing science into potentia... Read More
